Your Team for Swiss Law – now also in Geneva

Search filters

Anaveon closes CHF 35 m Series A financing

Anaveon, an immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the Novartis Venture Fund. The company was founded with financing from BaseLaunch,...

Oculis in-licenses novel phase II-stage Anti-TNF alpha antibody fragment

Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments in Lausanne, has entered into an agreement to in license a novel topical anti-TNF alpha antibody from Novartis. The...

Biovotion extends Series A Financing Round

VISCHER assists Harmony Medical Inc. as investor in the second closing of the ongoing CHF 10 m Series A financing round of Biovotion Ltd., Zürich. Biovotion Ltd is a leading wearable physiology monitoring company and provides...

Celgene acquires EngMab

Celgene (NASDAQ: CELG) has bought Swiss biotech EngMab for USD 600 million. EngMab's focus is on T-cell bispecific antibodies (TCBs). TCBs bind simultaneously to a target on a tumor cell and to the T-cell receptor complex, leading...

Decision of the Swiss Federal Administrative Court (Bundesverwaltungsgericht) Concerning the Rates of University Hospitals

The Swiss Federal Administrative Court (Bundesverwaltungsgericht) decided on important issues concerning the calculation of payment rates of university hospitals. VISCHER (Andreas Albrecht and Michael Waldner) represented the...

Sale and lease-back of kneipp-hof's operating real estate

Credit Suisse Real Estate Fund LivingPlus (CS REF LivingPlus) acquires all operating real estate from kneipp-hof Dussnang which leases the operating real estate back. The VISCHER Team, led by Benedict F. Christ (partner...

Vamed acquires kneipp-hof Dussnang AG

The international health care Provider VAMED (part of the German Fresenius group) extends its Swiss activities and acquires 100 percent of kneipp-hof Dussnang AG. This allows the seller, Kloster Heiligkreuz of Cham, to implement a...

Sonetik closes financing to fund further growth in the US

VISCHER advises Sonetik in a financing to fund further growth in the US. The participants in this Series A2 financing include existing investors, BB Biotech Ventures, and new investors joining the consortium, Aeris Capital. The...

You are currently offline. Some pages or content may fail to load.